CN113491655A - 一种祛痘护肤品的配方 - Google Patents
一种祛痘护肤品的配方 Download PDFInfo
- Publication number
- CN113491655A CN113491655A CN202010298670.1A CN202010298670A CN113491655A CN 113491655 A CN113491655 A CN 113491655A CN 202010298670 A CN202010298670 A CN 202010298670A CN 113491655 A CN113491655 A CN 113491655A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- acne
- skin
- skin care
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 30
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 29
- 239000000284 extract Substances 0.000 claims abstract description 22
- 239000000047 product Substances 0.000 claims abstract description 18
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 9
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 9
- 235000013719 Houttuynia cordata Nutrition 0.000 claims abstract description 6
- 241000405414 Rehmannia Species 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 241000736199 Paeonia Species 0.000 claims abstract description 5
- 244000236658 Paeonia lactiflora Species 0.000 claims abstract description 5
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims abstract description 5
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 5
- 241001278097 Salix alba Species 0.000 claims abstract description 5
- 241000186660 Lactobacillus Species 0.000 claims abstract description 4
- 241000972673 Phellodendron amurense Species 0.000 claims abstract description 4
- 238000000855 fermentation Methods 0.000 claims abstract description 4
- 230000004151 fermentation Effects 0.000 claims abstract description 4
- 239000000706 filtrate Substances 0.000 claims abstract description 4
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 4
- 235000015206 pear juice Nutrition 0.000 claims abstract description 4
- 229920002683 Glycosaminoglycan Polymers 0.000 claims abstract description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940059958 centella asiatica extract Drugs 0.000 claims abstract description 3
- 241000405911 Rehmannia glutinosa Species 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 235000013717 Houttuynia Nutrition 0.000 claims description 3
- 241001325266 Cordia Species 0.000 claims description 2
- VIZXMHCBZLGUET-UHFFFAOYSA-N sodium gualenate Chemical compound CC(C)C1=CC=C(C)C2=C(S(O)(=O)=O)C=C(C)C2=C1 VIZXMHCBZLGUET-UHFFFAOYSA-N 0.000 claims description 2
- 229950002760 sodium gualenate Drugs 0.000 claims description 2
- 244000144730 Amygdalus persica Species 0.000 claims 2
- 244000237986 Melia azadirachta Species 0.000 claims 2
- 235000013500 Melia azadirachta Nutrition 0.000 claims 2
- 235000004347 Perilla Nutrition 0.000 claims 2
- 244000124853 Perilla frutescens Species 0.000 claims 2
- 240000004534 Scutellaria baicalensis Species 0.000 claims 2
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims 2
- 235000011446 Amygdalus persica Nutrition 0.000 claims 1
- 239000004909 Moisturizer Substances 0.000 claims 1
- 235000006040 Prunus persica var persica Nutrition 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 239000007854 depigmenting agent Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000006254 rheological additive Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 9
- 230000028327 secretion Effects 0.000 abstract description 6
- FWKQNCXZGNBPFD-UHFFFAOYSA-N Guaiazulene Chemical compound CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 abstract description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 2
- 239000004519 grease Substances 0.000 abstract description 2
- 229960002350 guaiazulen Drugs 0.000 abstract description 2
- 239000011734 sodium Substances 0.000 abstract description 2
- 229910052708 sodium Inorganic materials 0.000 abstract description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 abstract description 2
- 230000006749 inflammatory damage Effects 0.000 abstract 1
- 230000037380 skin damage Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 20
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 5
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 241000186427 Cutibacterium acnes Species 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 3
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 235000011477 liquorice Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229940055019 propionibacterium acne Drugs 0.000 description 3
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 3
- 229940120668 salicin Drugs 0.000 description 3
- 230000005808 skin problem Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- QBDCOUHKEVYWLO-UHFFFAOYSA-N Decanoyl acetaldehyde Chemical compound CCCCCCCCCC(=O)CC=O QBDCOUHKEVYWLO-UHFFFAOYSA-N 0.000 description 2
- 206010054107 Nodule Diseases 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 229940084038 salix alba bark extract Drugs 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 240000001307 Myosotis scorpioides Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 description 1
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000758742 Saururaceae Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 150000001277 beta hydroxy acids Chemical class 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- -1 flavonoids compounds Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008099 melanin synthesis Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940082940 phellodendron amurense bark extract Drugs 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 description 1
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Abstract
目前，对大多数青少年受到粉刺肌肤的困扰，油脂过度分泌，炎症、皮肤受损是引发粉刺的主要诱因。本发明涉及一种祛痘护肤品的配方，配方中合约60～80份水、1～5份丁二醇、1～5份甘油、0.1～5份芍药(PAEONIA LACTIFLORA)根提取物，0.1～5份积雪草提取物、0.1～5份愈创木薁磺酸钠、0.1～5份鱼腥草(HOUTTUYNIA CORDATA)提取物、0.1～5份中国地黄(REHMANNIA CHINENSIS)根提取物、0.1～5份白柳(SALIX ALBA)树皮提取物、0.1～5份黄檗(PHELLODENDRON AMURENSE)树皮提取物、0.1～5份乳酸杆菌/梨汁发酵产物滤液、0.1～5份水解葡糖氨基聚糖。
Description
技术领域
本发明涉及一种祛痘护肤品配方，属于日化产品技术领域。
背景技术
根据一项调研报告，约95％的男性青少年受到粉刺和痤疮问题的困扰，而女性面临这类皮肤问题的比例是85％。近年来，随着环境中的潜在刺激物增加，生活习惯的改变，越来越多的人皮肤屏障受损，研究发现，皮肤屏障受损引起炎症也会导致粉刺等皮肤问题的产生。
普遍认为，粉刺产生的原因主要是油脂分泌过剩，阻塞毛孔。1996～1999年，α-羟基酸和β-羟基酸治疗油脂的过度分泌，然而这种治疗方法的效果不是完全理想，因为还有其它原因协同导致肌肤粉刺问题。粉刺主要有四种不同的表现，丘疹：由皮脂腺在毛囊口处堆积、角质物增生阻塞、毛囊口漏斗扩张所至。局部性突起，或小如针头，或大如黄豆，会有白或黑尖；脓疱：由丘疹演变而来，先演变成豌豆大水泡，数日后成为脓包。是毛囊壁破裂后在毛囊内形成的化脓性损害；结节：多发于两颊，红色，或隆起，呈半球形或圆锥形。由皮脂、游离脂肪酸、细菌和角化细胞自毛囊从破裂处进入真皮引发炎症所至；囊肿：红肿，其中有脓液，但无白尖，偶有脓液渗出。由于毛囊口堵塞，发生结节等损害，及皮脂腺受损，分泌物潴留，毛囊扩张而引起的。
根据Pillsbury法，按照病情的轻重，将痤疮分为I-IV度。
· I度(轻度)：黑头粉刺、散发炎性丘疹。
· II度(中度)：炎性丘疹数目增多、可密集，限于面部，或有浅在性脓疱。
· III度(重度)：在II度基础上出现结节损害，发生于面、颈、胸、背部。
· IV度(重度-集簇性)：在III度加囊肿、结节，易形成疤痕。
粉刺成因：1、内分泌失调——皮脂分泌过多；2、皮脂腺毛囊角化过度；3、痤疮丙酸杆菌等大量繁殖；4、毛囊周围炎症反应；遗传因素、某些食物、药物、化妆品等因素均可影响、诱发和加重痤疮的发生。粉刺可能产生其它皮肤问题，疤痕：丘疹，结节，囊肿的病理变化会造成真皮或深部组织缺损或破坏，当皮肤开始修复时，机体只能用新生结缔组织修复，形成坚实无弹性的疤痕。色素沉着：通常所说″红印″，是痤疮炎症后色素加深或紊乱引起，炎症介质和炎性细胞直接作用于色素细胞，使其加速其合成黑色素。轻度痤疮无明显炎症，不会留下色素变化；造成炎症反应者，最终会导致色素变化。
发明内容
粉刺的发生和发展和5α-还原酶密切相关，荷尔蒙在5α-还原酶的作用下转换成更强大的双氢睾酮，然后双氢睾酮激发皮脂腺的扩大，引起脂质分泌加剧，从而导致痤疮。芍药绽放时花朵硕大，花色艳丽，多用于形容美丽娇艳的女性，也被人们誉为″花相″，象征爱情，是中国七夕节的代表花卉。芍药根可入药，且已知与甘草共用能达到相乘功效，中医方剂中就有著名的″芍药甘草汤″一方。芍药提取物在护肤品中添加时，也多被认为能与抗炎类主剂产生相乘功效。
愈创木薁磺酸钠具有极为优异的抗炎、抗过敏、组织修复的功效，是目前粘膜抗炎修复领域，唯一兼具靶向抗炎和组织再生双重功效的物质。鱼腥草提取物为三白草科蕺菜属植物蕺菜的全草提取物，主要含挥发油、生物碱、多糖、有机酸和黄酮类等成分。对于人γ- 球蛋白在Cu2+存在下的热变性，鱼腥草也有显著抑制作用。鱼腥草素具一定抗炎活性，能显著抑制巴豆油、二甲苯所致小鼠耳肿胀、皮肤毛细血管通透性亢进，对HAC所致腹腔毛细血管染料渗出也有显著的抑制作用。鱼腥草所含槲皮素、槲皮苷及异槲皮苷等黄酮类化合物也具有显著抗炎作用，能显著抑制炎症早期的毛细血管通透性亢进。
中国地黄根提取物可以显著抑制5α-还原酶的活性，而且对纤聚蛋白增长有促进作用，表明有增强皮肤新陈代谢的作用，可改变皮脂的组成，结合它在低湿度环境下的吸湿能力，可应用于控油祛痘护肤品之中。白柳树皮提取物中的主要活性成分水杨苷不仅影响皮肤中基因的调控，还调控着与皮肤衰老生物学过程相关的基因群，这些基因群被称为功能性″年轻基因群组″。此外，水杨苷对皮肤中的关键蛋白之一胶原蛋白的产生和维持起着重要作用，因此能够增加皮肤弹性，达到抗皱功效。白柳树皮提取物不仅具有优异的抗衰老抗皱功效，还具有高效消炎活性。水杨苷因具有类阿司匹林属性，具有一定的消炎功效，可以用于缓解面部痤疮、疱疹性炎症和晒伤。
黄檗树皮提取物可以痤疮丙酸杆菌抑制活性，乳酸杆菌/梨汁发酵产物滤液富含糖、乳酸和矿物质。能柔滑肌肤、促进新陈代谢、改善皮肤弹性、保湿和减少皱纹，有助于粉刺后的皮肤修复，避免引起皮肤衰老和色素沉着。
本发明为一种祛痘护肤品的配方，具有抑制皮肤油脂过度分泌，抑制5α-还原酶的活性，抑制痤疮丙酸杆菌，抗炎，修复皮肤等功效。
一种祛痘护肤品的配方，配方中含约60～80份水、1～5份丁二醇、1～5份甘油、0.1～5 份芍药(PAEONIA LACTIFLORA)根提取物，0.1～5份积雪草提取物、0.1～5份愈创木薁磺酸钠、0.1～5份鱼腥草(HOUTTUYNIA CORDATA)提取物、0.1～5份中国地黄 (REHMANNIACHINENSIS)根提取物、0.1～5份白柳(SALIX ALBA)树皮提取物、0.1～5 份黄檗(PHELLODENDRON AMURENSE)树皮提取物、0.1～5份乳酸杆菌/梨汁发酵产物滤液、0.1～5份水解葡糖氨基聚糖。
配方中还可以含有至少一种皮肤调理剂如维生素C及衍生物、透明质酸钠、蓝铜肽、甘草提取物等。
本发明中还可含有植物甾醇类0.01～0.5份、氢化卵磷脂0.1～2.0份、甘油硬脂酸酯 0.1～0.5份、鲸蜡醇1～3份、硬脂醇1～3份、山嵛醇1～3份。
本发明的复合物产品可应用于控油和祛痘产品，但是不受剂型限制，如水、精华凝胶、乳化膏体等。
具体实施方式
本发明的实施例为：
一种祛痘护肤品的配方如表1
(单位为重量份)
表一：一种祛痘护肤品的配方
上述产品的调配方法为：将A组组分加入水锅中，并加热至70～75℃，搅拌均匀；，边搅拌边降温至50℃，加入B组组分；冷却至室温进行灌装即可。
本配方通过高低温稳定性测试。实验条件：48℃、4℃和光照放置3个月。
上述实例为本发明较佳的实施方式，但本发明的实施方式不受上述实施实例的限制。
Claims (3)
1.一种祛痘护肤品配方，配方含有：
a)60～80份水、1～5份丁二醇、1～5份甘油、0.1～5份芍药(PAEONIA LACTIFLORA)根提取物，0.1～5份积雪草提取物、0.1～5份愈创木薁磺酸钠、0.1～5份鱼腥草(HOUTTUYNIACORDATA)提取物、0.1～5份中国地黄(REHMANNIA CHINENSIS)根提取物、0.1～5份白柳(SALIX ALBA)树皮提取物、0.1～5份黄檗(PHELLODENDRON AMURENSE)树皮提取物、0.1～5份乳酸杆菌/梨汁发酵产物滤液、0.1～5份水解葡糖氨基聚糖。
b)至少一种外加成分。
2.如权利要求1中的护肤品配方，配方中的至少一种外加成分为溶剂、增稠剂、PH调节剂、保湿剂、流变调节剂、螯合剂、亮肤剂、防腐剂或皮肤调节剂中的一种或几种。
3.如权利要求1中的护肤品配方，还可含有桃(PRUNUS PERSICA)核仁提取物、紫苏(PERILLA OCYMOIDES)叶提取物、野大豆(GLYCINE SOJA)籽提取物、黄芩(SCUTELLARIABAICALENSIS)提取物、印度楝(AZADIRACHTA INDICA)叶提取物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010298670.1A CN113491655A (zh) | 2020-04-07 | 2020-04-07 | 一种祛痘护肤品的配方 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010298670.1A CN113491655A (zh) | 2020-04-07 | 2020-04-07 | 一种祛痘护肤品的配方 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113491655A true CN113491655A (zh) | 2021-10-12 |
Family
ID=77994930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010298670.1A Pending CN113491655A (zh) | 2020-04-07 | 2020-04-07 | 一种祛痘护肤品的配方 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113491655A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107349149A (zh) * | 2017-07-25 | 2017-11-17 | 广州铭心化妆品有限公司 | 一种祛痘精华液及其制备方法 |
| CN110151661A (zh) * | 2019-07-09 | 2019-08-23 | 汕头市皙皙里医药科技有限公司 | 一种美白祛斑、祛痘改善皮肤的组合物及其制备方法 |
-
2020
- 2020-04-07 CN CN202010298670.1A patent/CN113491655A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107349149A (zh) * | 2017-07-25 | 2017-11-17 | 广州铭心化妆品有限公司 | 一种祛痘精华液及其制备方法 |
| CN110151661A (zh) * | 2019-07-09 | 2019-08-23 | 汕头市皙皙里医药科技有限公司 | 一种美白祛斑、祛痘改善皮肤的组合物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111249209B (zh) | 一种保湿修护霜及其制备方法 | |
| CN109549917A (zh) | 一种具有抗敏舒缓功效的护肤组合物及其应用和制备方法 | |
| KR101991830B1 (ko) | 미네랄이 풍부한 온천수로 추출한 감초 및 병풀 추출물을 함유하는 화장품 조성물 | |
| WO2017092176A1 (zh) | 一种美白抗皱中药组合物及其混合提取物和应用 | |
| CN100558340C (zh) | 葫芦科油用于抑制5α-还原酶活性的应用 | |
| CN107375068A (zh) | 一种激素舒缓精华液及其制备方法 | |
| CN109662904A (zh) | 一种具有美白抗氧化功效的护肤组合物及其应用和制备方法 | |
| CN110292552A (zh) | 一种具有抗敏修复功效的复方植物提取物及其制备方法和应用 | |
| CN112535652A (zh) | 一种光感赋活原液及其制备方法 | |
| KR20080099570A (ko) | 복합 생약 추출물을 유효성분으로 함유하는 피부염 질환의예방 및 치료용 조성물 | |
| CN105662949A (zh) | 具有美白功效的化妆品组合物及其制备方法和应用 | |
| CN110585044B (zh) | 一种含金钗石斛复方中药组合物及其制备方法 | |
| CN111419773A (zh) | 一种皮肤抗衰修复植物提取物组合物及应用与含该组合物的精华乳 | |
| CN102232917A (zh) | 一种中药组合提取物在美白保湿产品中的应用 | |
| KR20140145278A (ko) | 피부 수렴 및 탄력 효과를 갖는 승마 추출물, 산수유 추출물 및 현초 추출물을 함유하는 화장료 조성물. | |
| KR20080077762A (ko) | 탈모방지 및 모발생장 촉진 효과를 가지는 생약화장료조성물 | |
| CN104013549B (zh) | 一种含中华金丝提取物的护肤品 | |
| CN113491655A (zh) | 一种祛痘护肤品的配方 | |
| KR101914969B1 (ko) | 한방복합발효추출물을 함유하는 모발용 화장료 조성물 | |
| KR101252560B1 (ko) | 봉숭아 추출물을 함유하는 여드름 개선용 화장료 조성물 | |
| KR102142461B1 (ko) | 구상나무 추출물을 포함하는 피부 상태 개선용 조성물 | |
| CN105342966A (zh) | 含有日本医蛭的护肤保湿霜及其制备方法 | |
| KR20170003073A (ko) | 칼라테라피에센스 마스크팩 | |
| CN115414308A (zh) | 一种祛痘组合物及制备方法和应用 | |
| KR20090103041A (ko) | 생약제 추출물을 함유하는 화장료 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |